42 results about "Tuberculosis prevention" patented technology

The invention discloses a tuberculosis prevention and treatment drug preparation device which comprises a support frame fixedly mounted on a bottom plate and an inlaying seat body mounted on the rightend surface of the support frame by a lifting device, foot columns are fixedly arranged around the bottom end surface of the bottom plate, rollers are cooperatively disposed in the bottom end surfaces of the foot columns in a rolling manner, and the bottom end surface of the inlaying seat body is provided with a buffer cavity. A preparation seat body is slidably cooperatively disposed in the buffer cavity, suppressing members are left-right symmetrically disposed on the top end of the preparation seat body, and the top ends of the suppressing members are fixedly connected to the inner wall ofthe buffer cavity. The inner wall of the preparation seat body is provided with a transfer chamber, the upper side of the transfer chamber is provided with a guiding cavity, the inner bottom wall ofthe transfer chamber is provided with a steering chamber in a communication manner, the steering chamber penetrates the bottom end surface of the preparation seat body, a steering column is rotatablycooperatively disposed in the steering chamber, and the bottom portion of the steering column extends out of the bottom end surface of the preparation seat body, and is cooperatively provided with a grinding wheel.

The invention discloses a vaccine for preventing tuberculosis, a combined medicine, a preparation method and an application, and belongs to the field of medicines for treating latent infection of tuberculosis. Aiming at the problems that the existing subunit vaccines are ineffective or poor in treating people with latent tuberculosis infection, many types of adjuvants are used, and there are risks of hypersensitivity reactions and Koch reactions, the present invention provides a prevention method containing a mycobacterial microbial compound adjuvant Tuberculosis vaccine, which comprises Ag85b protein, ESAT6-CFP10 protein and Mycobacterium vaccae cell extract. The tuberculosis prevention vaccine containing the mycobacterial microbial compound adjuvant of the present invention is used for treating latent tuberculosis infection, and the effect is remarkable.

The invention discloses a mycobacterium tuberculosis drug-resistant mutant gene detection kit comprising: (1) a gene chip which has (i) a nucleotide probe, wherein the probe is a sequence of SEQIDNos: 1-31 or a complementary sequence of SEQIDNos: 1-31, (ii) a DNA sequence labeled with biotin points, wherein the sequence is SEQIDNO. 32, (iii) an IS6110DNA sequence of a mycobacterium tuberculosis complex, wherein the sequence is SEQIDNo. 33; (2) various primers used for amplifying DNA sequences in clinical samples, wherein the DNA sequences of the primers are SEQIDNos. 34-41. The kit of the invention detects the drug resistance of mycobacterium tuberculosis to rifampin and isoniazid, provides reference basis for the prevention and treatment of tuberculosis, and has significant meaning.

The invention provides a preparation method of recombinant protein CFP-10 nanoparticles and the application thereof in preparing tuberculosis prevention vaccines. The preparation method includes the steps of (1) configuration of a polylactic acid-glycolic acid copolymer PLGA solution; (2) configuration of a recombinant protein CFP-10 solution; (3) preparation of primary emulsion; (4) preparation of compound emulsion; (5) formation of the nanoparticles. The recombinant protein CFP-10 nanoparticles prepared by the preparation method are used for enhancing the immunity of BCG-immunized mice through intranasal drip, and it is confirmed that the recombinant protein CFP 10 nanoparticles have the effects of improving mucosal immunity level and promoting BCG immunity.

The invention belongs to the field of biological medicine, and particularly relates to a tubercular mosaic type DNA (Deoxyribonucleic Acid) vaccine. The tubercular mosaic type DNA vaccine solves the technical problems of nonideal medicine effect and bad safety of the traditional mosaic vaccine. The technical scheme is as follows: the mosaic type DNA vaccine contains the encoding gene of HSP 70 / CD 80 mosaic protein and can express the encoding gene in vivo. After using a pVAXI carrier, the tubercular mosaic type DNA vaccine disclosed by the invention has a better effect on the prevention and treatment of tuberculosis and can especially be used for inducing stronger Th1 type reaction and better prevent and treat tuberculosis; and besides, the pVAXI carrier has kanamycin resistance, cannot cause any anaphylactic reaction and can better prevent and immunologically treat tuberculosis.